Sign in
Taking people in United StatesPhase 1/2

A Study of TSRA-196 in Adults With PiZZ Alpha-1 Antitrypsin Deficiency (AATD)

Key facts

Who runs it
Tessera Therapeutics, Inc.
Where
Boston, Charleston, Jacksonville, Rochester, and Seattle, United StatesSee the 5 sitesAlso in 5 other countries, 8 sites
Status
Recruiting
Phase
Phase 1/2
People taking part
72 people, planned
Started
21 Apr 2026
Expected to end
Mar 2029
Type of study
Interventional
Treatments tested
  • TSRA-196
Record updated
12 November 2026

Who can take part

Age
18 years to 70 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 27 criteriaShow less

Who can take part

  • Males or females who are 18 to 70 years of age, inclusive, at the time of signing the informed consent
  • Body mass index of 18 to 37 kg/m2, inclusive
  • Confirmed diagnosis of AATD and PiZZ genotype
  • At least one previous measure of blood total AAT level <11 µmol/L
  • Nonsmoker for at least 6 months before screening and must remain nonsmoking for the entire study duration
  • Either AAT treatment-naïve or washed out of all investigational or approved treatments that modify AAT levels for 5 half-lives or at least 4 weeks, whichever is longer, before TSRA-196 administration; Parts 1A and 2A (AATD lung disease with no or minimal liver fibrosis)
  • Clinically significant lung disease, defined as 1) evidence of emphysema or bronchiectasis by computed tomography or 2) DLCO <70% of the predicted value or 3) ppFEV1 <80%
  • ppFEV1 ≥35%
  • METAVIR fibrosis score F0 or F1 confirmed by liver biopsy at screening, or a liver stiffness measure by FibroScan ≤7 kPa at screening
  • FIB-4 index score ≤3.25 at screening
  • ALT and/or AST <ULN at screening; Parts 1B and 2B (AATD liver disease with significant or severe liver fibrosis, with or without AATD lung disease)
  • METAVIR fibrosis score F2 or F3 confirmed by liver biopsy at screening. A liver biopsy conducted within 12 months before screening is acceptable as a substitute
  • Liver stiffness measure by FibroScan >7 and ≤15 kPa at screening
  • ALT and/or AST <2 x ULN at screening

Who cannot take part

  • History of one or more hospitalizations due to severe exacerbation of underlying lung disease during the year before screening or received IV antibiotics for treatment of a pulmonary infection within 6 months before screening
  • Lung volume reduction surgery within 1 year before screening or plan to receive lung volume reduction surgery during the study period
  • Documented chronic need for positive airway pressure therapy beyond nocturnal use
  • Has received an organ transplant or is on a waiting list for an organ transplant
  • Prior treatment with gene therapy using viral vectors or intended to permanently change the patient's DNA
  • Any investigational products within 30 days before dosing or plan to take an investigational product before the end of study
  • History of liver disease unrelated to AATD, or history of or clinical signs of cirrhosis
  • Significant lung disease not attributable to manifestations of AATD, as determined by the investigator
  • Seropositive for human immunodeficiency virus (HIV) (HIV-1 or HIV-2)
  • Seropositive for hepatitis B (hepatitis B surface antigen [HBsAg] or hepatitis B core antibody [HBcAb] positive) with detectable HBV DNA
  • Hepatitis C virus (HCV) RNA positive at screening (Parts 1A and 2A), or HCV RNA positive and/or HCV antibody positive at screening (Parts 1B and 2B)
  • Presence of genetic variation in SERPINA1 gene that may disrupt the function of TSRA-196, determined by screening genotyping
  • Unstable AATD-related COPD, as determined by the investigator, or severe bronchiectasis

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 70 years old?

Where in United States

Also in 5 other countries, 8 sites

  • Clinical Study CenterBoston, United StatesTaking people
  • Clinical Study CenterCharleston, United StatesTaking people
  • Clinical Study CenterJacksonville, United StatesTaking people
  • Clinical Study CenterRochester, United StatesTaking people
  • Clinical Study CenterSeattle, United StatesTaking people

About the trial

What the trial wants to find out

This is a Phase 1/2, open-label, multi-center, dose escalation (Part 1), dose expansion (Part 2), and single repeat dose (Part 3) study to evaluate the safety, tolerability, efficacy, and PK/PD parameters of TSRA-196 in adults with the PiZZ genotype who have lung and/or liver disease associated with severe alpha-1 antitrypsin deficiency (AATD)

The group in the trial

  • TSRA-196 Drug ProductTreatment being tested

    Treatment: TSRA-196

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase 1/2, Open-Label, Multi-Center, Dose Escalation, Dose Expansion, and Single Repeat Dose Study of TSRA-196 in Adults With the PiZZ Genotype Who Have Lung and/or Liver Disease Associated With Severe Alpha-1 Antitrypsin Deficiency
Criteria questions
Built from NCT07227207, who can take part
Record updated
12 November 2026